Artivion, Inc. (NYSE:AORT – Get Free Report) CAO Amy Horton sold 12,430 shares of the company’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $26.18, for a total transaction of $325,417.40. Following the completion of the transaction, the chief accounting officer now owns 139,989 shares in the company, valued at $3,664,912.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Artivion Trading Up 0.2 %
AORT stock traded up $0.06 during midday trading on Wednesday, hitting $26.33. The company had a trading volume of 173,589 shares, compared to its average volume of 226,079. The stock has a market cap of $1.10 billion, a price-to-earnings ratio of -109.46 and a beta of 1.74. Artivion, Inc. has a 52 week low of $12.16 and a 52 week high of $29.24. The company has a current ratio of 5.63, a quick ratio of 4.04 and a debt-to-equity ratio of 1.07. The stock’s 50 day moving average price is $25.79 and its 200 day moving average price is $24.01.
Artivion (NYSE:AORT – Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.04. Artivion had a negative net margin of 2.22% and a positive return on equity of 3.81%. The company had revenue of $98.02 million during the quarter, compared to analyst estimates of $97.70 million. As a group, equities research analysts expect that Artivion, Inc. will post 0.2 earnings per share for the current fiscal year.
Institutional Trading of Artivion
Analyst Ratings Changes
AORT has been the subject of several research analyst reports. Lake Street Capital lifted their price target on Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday, July 2nd. Oppenheimer increased their price target on shares of Artivion from $25.00 to $30.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. Stifel Nicolaus boosted their price objective on shares of Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a report on Friday, September 13th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $30.00 target price on shares of Artivion in a report on Friday, September 27th.
Read Our Latest Research Report on Artivion
About Artivion
Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.
Featured Articles
- Five stocks we like better than Artivion
- Compound Interest and Why It Matters When Investing
- S&P 500 Hitting Resistance: These 3 Stocks Offer the Best Upside
- What is a SEC Filing?
- Nike’s Post-Earnings Drop Presents a Buying Opportunity
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Microsoft’s Targeted Upside Might Be Too Good to Ignore
Receive News & Ratings for Artivion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artivion and related companies with MarketBeat.com's FREE daily email newsletter.